Xenon Pharmaceuticals (XENE) Phase 2b 'X-TOLE' Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy Met its Primary Efficacy Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. ROIV
2. HUVR:IN
3. ASML
4. NVS
5. TTE
6. ANET
7. NKE
8. BE
9. PANW
10. CL

Go back to Xenon Pharmaceuticals (XENE) Phase 2b 'X-TOLE' Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy Met its Primary Efficacy Endpoint
(NASDAQ: XENE) Delayed: 59.75 --0 (-0%)
Previous Close $59.75    52 Week High $9.75 
Open $59.75    52 Week Low $5.65 
Day High $59.75    P/E N/A 
Day Low $59.75    EPS $0.00 
Volume 1,043